

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

**Date of Report: May 10, 2018**  
**Commission File Number: 001-36891**

**Collectis S.A.**

(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry  
75013 Paris, France  
+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:  
Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

---

## EXHIBIT INDEX

<u>Exhibit</u>	<u>Title</u>
<a href="#">99.1</a>	<a href="#">Press release, dated May 10, 2018</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**CELLECTIS S.A.**  
(Registrant)

May 10, 2018

By: /s/ André Choulika  
André Choulika  
Chief Executive Officer

## Collectis to Present Data at the 2018 ASGCT Annual Meeting

NEW YORK--(BUSINESS WIRE)--May 10, 2018--Regulatory News:

Collectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that three posters regarding the Company's allogeneic off-the-shelf CAR-T product candidates and one poster associated with the Company's technology will be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting to be held from May 16 to 19, 2018, in Chicago, Illinois.

- ***Universal CAR T-Cells Targeting CS1 (UCARTCS1) for the Treatment of Multiple Myeloma***

Agnès Gouble<sup>1</sup>, Roman Galetto<sup>1</sup>, Rohit Mathur<sup>3</sup>, Stephanie Filipe<sup>1</sup>, Isabelle Chion-Sotinel<sup>1</sup>, Jing Yang<sup>3</sup>, Jin He<sup>3</sup>, Robert Z. Orłowski<sup>3</sup>, Sattva S. Neelapu<sup>3</sup> and Julianne Smith<sup>2</sup>

<sup>1</sup>Collectis SA, 8 rue de la croix Jarry, 75013 Paris, France

<sup>2</sup>Collectis, Inc., 430 East 29th Street, 10016 New York, NY

<sup>3</sup>Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030

Poster number: 130

Cancer - Targeted Gene & Cell Therapy I

Wednesday, May 16, 2018 at 5:30 PM - Stevens Salon C, D

- ***Repurposing endogenous immune pathways to improve chimeric antigen receptor T-cells potency***

M. Sachdeva<sup>1</sup>, B. Busser<sup>1</sup>, S. Temburni<sup>1</sup>, A. Juillerat<sup>1</sup>, L. Poirot<sup>2</sup>, P. Duchateau<sup>2</sup>, J. Valton<sup>1</sup>;

<sup>1</sup>Collectis, Inc., New York, NY

<sup>2</sup>Collectis, Paris, France

Poster number: 774

Cell Therapies III

Friday, May 18, 2018 at 5:45 PM - Stevens Salon C, D

- **Engineering CAR T-Cells with an Integrated off Switch to Enhance Safety Performance**

Alexandre Juillerat<sup>1</sup>, Diane Tkach<sup>1</sup>, Brian W. Busser<sup>1</sup>, Sonal Temburni<sup>1</sup>, Julien Valton<sup>1</sup>, Aymeric Duclert<sup>2</sup>, Laurent Poirot<sup>2</sup> and Philippe Duchateau<sup>2</sup>

<sup>1</sup>Collectis, Inc., 430E, 29th Street, NYC, NY 10016

<sup>2</sup>Collectis SA, 8 rue de la Croix Jarry, 75013 Paris, France

Poster number: 739

Cancer - Immunotherapy, Cancer Vaccines III

Friday, May 18, 2018 at 5:45 PM - Stevens Salon C, D

Presented by Allogene Therapeutics, Inc.:

- **Cynomolgus macaque gene-edited CAR T-cell platform: towards a reliable in vivo allogeneic model to assess safety and Efficacy**

Diego A. Vargas-Inchaustegui<sup>1</sup>, Rory Dai<sup>1</sup>, Alexandre Juillerat<sup>2</sup>, Christopher Do<sup>1</sup>, Kris Poulsen<sup>1</sup>, Thomas Pertel<sup>1</sup>, Barbra Sasu<sup>1</sup>

<sup>1</sup>Allogene Therapeutics, Inc., South San Francisco, CA,

<sup>2</sup>Collectis, Inc., New York, NY

Poster number: 131

Cancer - Targeted Gene & Cell Therapy I

Wednesday, May 16, 2018 at 5:30 PM - Stevens Salon C, D

Abstracts are available on the ASGCT website. The 4 posters to be presented at the 2018 ASGCT Annual Meeting will be available on the Collectis website after May 19, 2018.

### About Collectis

Collectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Collectis uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets.

Collectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: [www.collectis.com](http://www.collectis.com)

Talking about gene editing? We do it. TALEN® is a registered trademark owned by Collectis.

## Disclaimer

This press release contains “forward-looking” statements that are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Further information on the risks factors that may affect company business and financial performance, is included in Collectis’ Annual Report on Form 20-F for the year ended December 31, 2017 and subsequent filings Collectis makes with the Securities and Exchange Commission from time to time. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

###

### CONTACT:

**For further information, please contact:**

#### **Media contacts:**

Collectis

Jennifer Moore, 917-580-1088

VP of Communications

[media@collectis.com](mailto:media@collectis.com)

or

KCSA Strategic Communications

Caitlin Kasunich, 212-896-1241

[ckasunich@kcsa.com](mailto:ckasunich@kcsa.com)

or

#### **Collectis IR contact:**

Simon Harnest, 646-385-9008

VP of Corporate Strategy and Finance

[simon.harnest@collectis.com](mailto:simon.harnest@collectis.com)